MAPT and Alzheimer disease: By addressing various facets of pathology, combining several biomarkers, such as Aβ42, t-tau, and p-tau, improves diagnosis accuracy in AD; for example, a greater indication of AD is provided by the combination of increased p-tau and decreased Aβ42 than by either biomarker alone, increasing early diagnosis sensitivity and specificity [45,52].